Ropinirole is widely distributed throughout the body and protein binding is approximately 40%. Symptoms of an allergic reaction may include:swelling of the face, lips, mouth, tongue, or throatWhat should I tell my healthcare provider before taking Ropinirole tablets?Before you take Ropinirole tablet, tell your healthcare provider if you:How should I take Ropinirole tablets for Parkinson’s disease?It may take several weeks before you reach a dose that controls your symptoms.What are the possible side effects of Ropinirole tablets? For patients who were responders at Week 24, the mean dose of Ropinirole tablets were 2 mg (range: 0.25 to 4 mg). In the clinical development program (N = 613), 2 patients treated with REQUIP XL had pleural effusion. Overall, 7% of patients treated with any dose of REQUIP XL, including 6% during the titration phase, discontinued prematurely from the study because of adverse reactions compared with 5% of patients on placebo. In clinical trials, more than 88% of a radiolabeled dose was recovered in urine and the absolute bioavailability was 45% to 55%, indicating approximately 50% first-pass effect.Relative bioavailability from a tablet compared with an oral solution is 85%. you can ask your healthcare provider or pharmacist for information about Ropinirole tablets that is written for healthcare professionals.People with RLS should take Ropinirole tablets differently than people with parkinson’s disease (see “Tell your healthcare provider if you have any side effect that bothers you or does not go away.Medicines are sometimes prescribed for purposes other than those listed in a patient information leaflet. Of patients who received a dose greater than 24 mg/day, reported symptoms included adverse events commonly reported during dopaminergic therapy (nausea, dizziness), as well as visual hallucinations, hyperhidrosis, claustrophobia, chorea, palpitations, asthenia, and nightmares. A second trial compared REQUIP XL with REQUIP tablets in patients with early Parkinson’s disease not receiving L-dopa (Study 3). This was followed by 3 consecutive 8-week maintenance periods, during which patients were either maintained on the prior formulation or switched to the alternative formulation. In a flexible-dose trial, patients with early Parkinson’s disease were treated with REQUIP XL or the immediate-release formulation of REQUIP without L-dopa. In these trials, either Ropinirole tablets or placebo was used as an adjunct to L-dopa.In the double-blind, placebo-controlled trials in patients with RLS, the most commonly observed adverse reactions in patients treated with Ropinirole tablets (incidence at least 5% greater than placebo) were nausea, vomiting, somnolence, dizziness, and asthenic condition (i.e., asthenia, fatigue, and/or malaise).Approximately 5% of patients treated with Ropinirole tablets who participated in the double-blind, placebo-controlled trials in the treatment of RLS discontinued treatment due to adverse reactions compared with 4% of patients who received placebo. Based on individual patient therapeutic response and tolerability, if necessary, the dose should then be titrated with weekly increments as described in Table 1. Some have reported these events more than 1 year after initiation of treatment.In controlled clinical trials, somnolence was commonly reported in patients receiving Ropinirole tablets and was more frequent in Parkinson's disease (up to 40% Ropinirole tablets, 6% placebo) than in Restless Legs Syndrome (12% Ropinirole tablets, 6% placebo) It has been reported that falling asleep while engaged in activities of daily living usually occurs in a setting of preexisting somnolence, although patients may not give such a history. Vital signs should be maintained, if necessary.In the Parkinson’s disease program, there have been patients who accidentally or intentionally took more than their prescribed dose of Ropinirole. The percentage of patients discontinuing prematurely because of an adverse reaction was 8% for REQUIP XL 2 mg, 5% for REQUIP XL 4 mg, 8% for REQUIP XL 8 mg, 5% for REQUIP XL 12 mg, and 15% for REQUIP XL 24 mgIn the fixed-dose trial in advanced Parkinson’s disease (Study 2), 11% of patients on REQUIP XL exhibited a shift in serum creatine phosphokinase (CPK) from normal at baseline to above the normal reference range during treatment, compared with 6% of patients on placebo.